Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159)
Open Access
- 10 September 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-7
Abstract
Background: Prostate cancer (PCa) is the second most common cancer among men. New imaging-modalities have increased the diagnosed patients with limited number of metastasis after primary curative therapy, introducing so-called oligometastatic state. Stereotactic body radiotherapy (SBRT) is emerging as a low-toxicity treatment to erase PCa localizations and postpone androgen deprivation therapy (ADT). A deeper understanding of the predictive role of biomarkers is desirable for a targeted treatment selection and surveillance programs. The aims of the RADIOSA trial are: Compare SBRT +/− ADT for oligorecurrent-castration-sensitive PCa (OCS-PCa) in terms of efficacy, toxicity and Quality of Life (QoL). Develop biology/imaging based prognostic tool that allows identifying OCS-PCa subclasses. Methods: This is a randomized phase II clinical trial, recruiting 160 OCS-PCa in 3 years, with progression-free survival (PFS) as primary endpoint. Three tasks will be developed: Randomized clinical study (3 years for accrual and 2 years for follow-up and data analysis); Imaging study, including imaging registration and METastasis Reporting and Data System (MET-RADS) criteria; Pre-clinical study, development of a biobank of blood samples for the analysis of neutrophil-to-lymphocyte ratio and preparatory for a subsequent miRNA profiling. We aim to determine which arm is justified for testing in a subsequent Phase III trial. A decision-tree algorithm, based on prognosis, biological phenotype and imaging profile, will be developed. Discussion: Recruiting will start in July 2019. SBRT will allow obtaining excellent PFS, local control, QoL and low toxicity. In SBRT arm, ADT deferral will allow for a drug-holiday, delaying the detrimental impact on QoL. A sufficient number of blood samples will be collected to perform biological patient profiling. A stratification tool will be established with an analysis of morphological and functional imaging, based on the use of MET-RADS criteria. So, in conclusion, RADIOSA aims to define the optimal management of bone/nodal PCa relapses in a SBRT regimen. This study will increase our knowledge on low-burden metastatic PCa in the era of high precision and high technology personalized medicine, offering highly effective therapy in terms of clinical outcome and cost-effectiveness. Trial registration: The RADIOSA study was prospectively registered at clinicaltrials.gov (NCT03940235, May 2019).Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG-22159)
This publication has 29 references indexed in Scilit:
- Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancerUrologic Oncology: Seminars and Original Investigations, 2013
- Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation TherapyClinical Genitourinary Cancer, 2013
- Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancerFrontiers in Oncology, 2013
- Stereotactic body radiotherapy for oligometastasesThe Lancet Oncology, 2013
- Salvage Lymph Node Dissection with Adjuvant Radiotherapy for Nodal Recurrence of Prostate CancerJournal of Urology, 2012
- PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate CancerBritish Journal of Medical and Surgical Urology, 2012
- Oligometastases revisitedNature Reviews Clinical Oncology, 2011
- Quality of life three years after diagnosis of localised prostate cancer: population based cohort studyBMJ, 2009
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening TrialsJournal of Clinical Oncology, 2005
- Whole Body Irradiation—Radiobiology or Medicine?British Journal of Radiology, 1953